A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study of the efficacy,
safety, and tolerability of subcutaneously administered Xolair as add-on therapy for the
treatment of subjects aged 12-75 years old diagnosed with moderate to severe asthma who are
inadequately controlled with high-dose inhaled corticosteroids (ICS)+ long-acting
beta-agonists (LABA) with or without additional controller therapy.